This is the authors' abstract. We don't add key points for this paper.
Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammationhttps://bit.ly/3KE1BH4
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Meteran et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: